SUMMARY
It has been demonstrated that components of the RAS such as angiotensinogen, renin, angiotensin-converting enzyme (ACE) and angiotensin II receptors exist within the heart and may function independently from circulating RAS.') The variability of the phenotypic expression of LVH in patients with HCM indicates a potential role for additional modifying genes . [1] [2] [3] [4] [5] [6] [7] [8] In the RAS, angiotensinogen is cleaved by renin to produce the inactive peptide angiotensin L9> The ACE then converts angiotensin I to angiotensin II; the latter peptide has various effects including vasoconstriction, aldosterone production, and enhanced noradrenalin release from sympathetic nerve endings. Angiotensin II also has hypertrophic, and possibly hyperplastic, effects on vascular smooth muscle cells and cardiomyocytes,2> and increases extracellular collagen matrix synthesis. The plasma concentration of angiotensinogen, the substrate for renin, is another clear determinant of angiotensin II levels.9) In a recent study we found that the T allele of the M235T polymorphism of the angiotensinogen gene in sporadic HCM patients is associated with LVH.10> Most of the known actions of angiotensin II, an effector peptide in the renin-angiotensin system, are exerted through the angiotensin II type 1 receptor (AGT,R), which is present in particular vascular smooth muscle cells and the myocardium. Gene variants in the AGT, receptor genes have been found to interact with the ACE gene to increase the risk of myocardial infarction") and have been associated with hypertension. 12) Chronic mechanical stress such as hypertension is thought to be a primary cause of LVH, whereas angiotensin H has a trophic action on cardiac myocytes and proliferates fibroblasts leading to LVH independent of mechanical stress. Because of these findings and the importance of the RAS in cardiovascular regulation,") the present study was designed to assess the contribution of the polymorphisms of the angiotensin II type 1 receptor (AGT,R A' 166C) gene on development of LVH with or without systemic hypertension. In addition, we explored interactions between AGT,R A'166C and other RAS genes (ACE and angiotensinogen genes, determined previously in this same population) in relation to LVH. consisted of 1 min at 94°C, 1 min at 56°C, and 1 min at 72°C. To prevent contamination with other unexpected DNA during PCR, all reaction reagents except for each primer and the genomic DNA of interest were treated in a UV cross linker (Stratalinker UV Cross Linker, STRATAGENE) and a reaction control without primers was prepared for every 5 tubes as a negative control. The 2 µl of unpurified product was diluted to 10 µl in the recommended restriction buffer containing 0.3 units of DdeI (New England Biolabs, Beverly, MA, USA). After restriction-endonuclease digestion for at least three hours at 37°C, samples were applied to 10 percent polyacrylamide gel, subjected to electrophoresis at 150 V for 60 minutes and visualized by ethidium bromide (Figure) . Statistical analysis: Values are expressed as mean ± SD. Nonparametric tests were used for two group comparisons (Mann-Whitney test) and analysis of variance (Kruskall-Wallis test). A p value < 0.05 was considered statistically significant.
Allele frequencies were deduced from genotype frequencies and differences between groups were tested by chi-squared analysis with one degree of freedom. Odds ratios and their 95% confidence intervals were calculated using the low-risk reference group (healthy subjects) to evaluate the effect of angiotensin II type 1 receptor gene AGT,R A' 166C polymorphism on the risk of development of car-diac hypertrophy.
We chose this reference group to represent a baseline level of risk, so that we could estimate the effect of having the C allele, as well as the risks posed by homozygotes.
RESULTS
Age, systolic and diastolic blood pressure, and left ventricular maximum wall thickness of the total subject group are shown in Table I . There were no significant differences in sex and age between any groups. Blood pressures showed no significant difference between healthy controls, HCMs patients and HCM relatives by ANOVA (Kruskal-Wallis test). HCM relatives and healthy controls all had normal wall thickness (<11mm). Angiotensin II type 1 receptor gene polymorphism:
As shown in Table II Genotypic proportions were in Hardy-Weinberg equilibrium in HCM rela- tives V (v2 = 0.003), but deviated in the group of healthy controls (X'= 5.73); however, the power to test deviations from such expected proportions is low, particularly when one of the homozygous classes is rare. Genotype dissociation was similar in the hypertensive LVH group and controls, relatives and controls, but not in the HCM patients and their relatives. The AA genotype frequency in patients with HCM was higher than in unaffected siblings and offspring (91.6% vs 80.2%, X2 = 4.96, p < 0.05). The odds ratio (an estimate of the relative risk of HCM between subjects with AA genotype and subjects with the AC or CC genotype) was 1.6 (95% CI 0.7-3.9, x2 = NS) in patients with HCM.
The frequency of the C allele among unaffected siblings and offspring was similar to that observed in healthy subjects without known hypertension and left ventricular hypertrophy (10.5% vs 7.5%). The C allele frequency in unaffected siblings and offspring was higher than in patients with HCM (10.5% vs 4.2%, X2= 5.3, p < 0.05). The A allele frequency was higher in HCM than in unaffected siblings and offspring (95.8% vs 89.5%, X2= 5.3, p < 0.05). Relationship between angiotensin II type 1 receptor and RAS genes polymorphisms: ACE D/I and angiotensinogen T235M genotypes were determined previously in this same population.'") No synergistic interactions have been observed in carriers of both AGTIR C and angiotensinogen T235 alleles. We observed a significant increase of the C and the D alleles in subjects with a family history of HCM without manifesting the disease (Table III) . Nine of 160 healthy subjects without known hypertension and left ventricular hypertrophy were carriers of both C and D alleles, whereas 18 among 105 relatives of HCM patients were both homozygote carriers (OR= 7.3, 95% CI 1.6-33.1; X2 = 7.9, p < 0.01). Carriers of both C and D alleles had a four-fold increase in the OR for family history of HCM without manifesting the disease. The number of subjects studied was relatively small and therefore our results might be open to interpretation, but a clear interrelation between genotypes and family history of HCM without manifesting the disease could be seen.
DISCUSSION
This study raised two interesting points concerning AGT1R A1166C polymorphism. First, C allele frequencies were markedly lower in HCM than in hypertensive LVH patients. Second, in subjects with a family history of HCM without manifesting the disease, a significant increase of both the C and D allele carrier states has been observed.
The RAS system, operating through stimulation of AGT1R by angiotensin II, has received intense interest as a mechanism for controlling cardiac hypertrophy.1,2,13) Chronic mechanical stress of the heart is a primary cause of LVH. The peptide hormone angiotensin II plays a principal role in regulating blood pressure and fluid homeostasis. Most of its known effects are mediated by guanine nucleotide-regulatory protein (G protein)-coupled receptor defined as the type 1 angiotensin II receptor or AGT1R. Characterization of cDNA and genomic clones shows that the human AGT1R gene contains five exons and encodes two receptor isoforms as a result of alternative splicing.15) The AGT2R might have a unique signalling regulatory mechanism and its expression is inversely related to the mitogenic activity of cells. 16) The cardiac RAS is often found activated in conditions of increased afterload or mechanical stress of myocytes. Cardiac expression of angiotensinogen and ACE is increased, resulting in elevated cardiac angiotensin II formation.1) This has been demonstrated in stretched cardiac myocytes in vitro as well as in animal models16-19) of pressure overload hypertrophy (supravalvular aortic stenosis and spontaneously hypertensive rats) and in human pressure overload hypertrophy20) (aortic stenosis).
Functional consequences of elevated angiotensin II levels may be vasoconstriction of the coronary vasculature and deterioration of diastolic function of the hypertrophied heart. Local formation of angiotensin II may also have a proliferative effect on connective tissue cells. Angiotensin II may thus be an important factor causing development and progression of LVH itself. The involvement of RAS in remodeling of the heart differs between different animal models of pressure overload-induced hypertrophy and may even differ within the same model for development versus maintenance of cardiac hypertrophy. It has been suggested that pressure overload produces cardiac hypertrophy without angiotensin II. [16] [17] [18] [19] In the gain-of-function16) study using gene transfer, it was shown that the The phenotypic expression of HCM among affected individuals sharing the same mutation varies markedly, 1,4,6-8) indicating a role for environmental factors and it is likely that many genes3-5"10) responsible for HCM remain to be identified. Possible genes modifying the pattern of hypertrophy could be the angiotensinconverting enzyme',') and angiotensinogen gene10J and their synergistic interaction.5,10-13, 21) It has been suggested that ACE gene polymorphism and ACE circulating levels might play a role in the myocardial hypertrophic process in HCM,3J especially in HCM with beta-MHC gene mutation.) In a recent study10J we found that the T allele of the M235T polymorphism of the angiotensinogen gene in sporadic HCM patients is associated with LVH. In an animal model, it has been shown that activation of the AGT,R receptor may not be important for mediating either cardiac hypertrophy"-") or myocardial fibrosis in the cardiomyopathic hamster.") An excess of the AGT,R C allele has been reported in severe hypertensives compared to normotensive subjects,") which suggests involvement of the AGT,R gene in the predisposition to hypertension. 13) However, no significant association between the AGT,R polymorphism and high blood pressure in the population as a whole has been found. ' 1,23-25) It has been suggested that the AGTIR C allele is associated with a modified response of the receptor to angiotensin IV') A strong interaction between ACE I/D and AGT,R A166C gene polymorphisms was found in the group of relatives of HCM patients in this study. We conclude that the molecular variant of the AGT,R A166C gene is not contributing to development of cardiac hypertrophy in hypertensive LVH and HCM patients, whereas carriers of both C and D alleles had a four-fold increase in the odds ratio for family history of HCM without manifesting the disease.
